Rolipram versus imipramine in inpatients with major, “minor” or atypical depressive disorder: A double-blind double-dummy study aimed at testing a novel therapeutic approach

A. Bertolino, D. Crippa, S. Didio, K. Fichte, G. Musmeci, V. Porro, V. Rapisarda, M. Sastre-Y-Hernandez, M. Schratzer

Research output: Contribution to journalArticlepeer-review

Abstract

Unlike conventional antidepressants, rolipram stimulates both the presynaptic as well as the postsynaptic component of monoaminergic transmisson. Several double-blind comparative trials are on the way to assess the clinical efficacy and safety of this novel compound. The present study was a randomized double-blind double-dummy comparison with imipramine in inpatients with major, “minor” and atypical depressions (DSM III). Results show no relevant differences between rolipram and imipramine regarding efficacy and safety.

Original languageEnglish
Pages (from-to)245-253
Number of pages9
JournalInternational Clinical Psychopharmacology
Volume3
Issue number3
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Rolipram versus imipramine in inpatients with major, “minor” or atypical depressive disorder: A double-blind double-dummy study aimed at testing a novel therapeutic approach'. Together they form a unique fingerprint.

Cite this